> Table 1 lists adverse reactions re ported for the 344patients trea ted with R eplagal in clinical trials, including 21 patients wi th history of end stage renal disease, 30paediatric patients ( ≤18years of age) and 17female pa tients, and from post -marketing spontaneous reports. Information is presented by system organ class and f requency (very common ≥1/10; common ≥1/100 to < 1/10; uncommon 
≥1/1,000 to < 1/100). The adverse reactions cat egorized as incid ence “not kn own (cannot beestimated from the available data)” are derived from post -marketin g spontaneous reports. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. The occurrence of an event in a single patient is defined as unc ommon in view of the number of patients treated. A single patient could be affected by several adverse re actions. The following adverse reactions have been identified for AGALSIDASE ALFA:Table 1System organ class Adverse rea ction
